SymbioCellTech is dedicated to providing the world with a permanent functional cure for diabetes.
Since 2006, SymbioCellTech has been developing a treatment to reduce or eliminate the need for external insulin therapy in insulin-dependent diabetes. This cellular therapeutic is based on the breakthrough innovations of Dr. Christof Westenfelder. The technology has been matured, refined, and rigorously tested in comprehensive preclinical trials. Based on the positive results of these tests, we have been granted FDA permission to conduct a pilot study in dogs, and are preparing for a pre-IND meeting to start clinical trials in humans.